An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In an effort to control non-medical use and/or medical abuse of prescription drugs, particularly prescription opioids, electronic prescription drug monitoring programs (PDMP) have been introduced in North-American countries, Australia and some parts of Europe. Paradoxically, there are simultaneous pressures to increase opioid prescribing for the benefit of individual patients and to reduce it for the sake of public health, and this pressure warrants a delicate balance of appropriate therapeutic uses of these drugs with the risk of developing dependence. This article discusses pros and cons of PDMP in reducing diversion of prescription opioids, without hampering access to those medications for those with genuine needs, and highlights tensions around PDMP implementation. DISCUSSION: PDMPs may help alleviate diversion, over-prescription and fraudulent prescribing/dispensing; prompt drug treatment referrals; avoid awkward drug urine test; and inform spatial changes in prescribing practices and help designing tailored interventions. Fear of legal retribution, privacy and data security, potential confusion about addiction and pseudo-addiction, and potential undue pressure of detecting misuse/diversion - are the major problems. There are tensions about unintended consequence of excessive regulatory enforcements, corresponding collateral damages particularly about inadequate prescribing for patients with genuine needs, and mandatory consultation requirements of PDMP. SUMMARY: In this era of information technology PDMP is likely to flourish and remain with us for a long time. A clear standard of practice against which physicians' care will be judged may expedite the utilisation of PDMP. In addition, adequate training on addiction and pain management along with public awareness, point-of-supply data entry from pharmacy, point-of-care real-time access to data, increasing access to addiction treatment and appropriate regulatory enforcement preferably through healthcare administration, together, may help remove barriers to PDMP use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steglitz, J., Buscemi, J., & Ferguson, M. J. (2012) · Translational Behavioral Medicine · doi:10.1007/s13142-012-0110-2 · Cited by 298
Cited by
Pauly, N. J., Slavova, S., Delcher, C., Freeman, P. R., & Talbert, J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.12.002 · Cited by 63
Bachhuber, M. A., Maughan, B. C., Mitra, N., Feingold, J., & Starrels, J. L. (2016) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.08.005 · Cited by 35
“…countries have implemented PMPs that are associated with reductions in potentially problematic prescribing; however, their impact on benzodiazepine safety (e.g., ED visits) is unclear (Gomes et al., 2014; Pradel et al., 2009; Dormuth, Miller, Huang, Mamdani, & Juurlink, 2012; Islam & McRae, 2014).”
Background
Metadata
- Authors
- Islam, M. M., & McRae, I. S.
- Venue
- BMC Pharmacology and Toxicology
- Published
- 2014-08-16
- Volume
- 15
- Issue
- 1
- Pages
- 46-46
- ISSN
- 2050-6511 (ISSN-L)
- OpenAlex
- W1985281481
- Cited by
- 93
- References
- 1
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions. https://app.cochat.ai/papers/10.1186/2050-6511-15-46
- The paper
- Islam, M. M., & McRae, I. S. (2014). An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions. BMC Pharmacology and Toxicology. https://doi.org/10.1186/2050-6511-15-46
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.